Overview

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
NewLink Genetics Corporation
Treatments:
Tryptophan